Bladder Bank (a Prospective Banking Study)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Non-Interventional Study.
- Who it may be relevant to
- Registry conditions: Bladder Carcinoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study collects blood and urine samples from patients with bladder cancer to support the development of tests for early detection of bladder cancer.
Detailed description
PRIMARY OBJECTIVE:
I. To establish a biobank of samples (blood and urine) to support the development of non-invasive tests for early detection of bladder cancer.
OUTLINE: This is an observational study.
Patients undergo blood and urine sample collection and have their medical records reviewed while on study.
Interventions
- Other Non-Interventional Study
Non-interventional study
Primary outcome measures
- Blood sample to support the development of non-invasive tests for early detection of bladder cancer [Time frame: Baseline (at enrollment)]
- Urine sample to support the development of non-invasive tests for early detection of bladder cancer [Time frame: Baseline (at enrollment)]
Eligibility criteria
Inclusion criteria
- Age \> 18 years
- Patient has undergone office-based evaluation for hematuria \[computed tomography (CT), ultrasound, cystoscopy\]
Exclusion criteria
- Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible)
- Patient has recurrent muscle invasive bladder cancer
- Patient has ever been previously diagnosed with UTUC (upper tract urothelial carcinoma) prior to bladder resection
- Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection
- Patient has had any prior radiation therapy to the target lesion prior to current collection
- Patient has had a biopsy to the target organ and/or lesion within 3 days before collection
- Patient has undergone cystectomy or cystoprostatectomy
- Patient has transurethral instrumentation (placement of urinary catheter) within 7 days prior to urine collection
- Patient has had a urinary tract infection within 14 days prior to urine collection
- Patient has chronic indwelling urinary catheter
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
United States · 1 center
- Mayo Clinic in Rochester — Rochester
Identifiers
NCT: NCT06109857 · 21-009854 · NCI-2023-00644 · 21-009854